We are developing a therapeutic designed to break the cancer-causing interaction between RAS and PI3Kα that does not harm healthy cells, bypasses glucose metabolism signaling, and avoids hyperglycemia. From company websiteSource · Oct 13, 2026
Keywords: lung non-small cell carcinomaoncologysolid tumorsHER2 positive breast cancer
Location: South San Francisco, CA · source · Oct 15, 2026